BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
33046048
Number of visits today
4580
Number of downloads
16241658
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Gisbert JP, Chaparro M. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. Gastroenterología y Hepatología (English Edition) 2018;41:389-405. [DOI: 10.1016/j.gastre.2018.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Abidin AZ, Snoswell CL, Shafiee Hanjani L, Callaghan G, Edmonds M. Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity. J Pharm Pract Res 2021;51:358-73. [DOI: 10.1002/jppr.1754] [Reference Citation Analysis]
2 Susanna F, Pavesio C. Okuläre Nebenwirkungen von biologischen Anti-TNF-Medikamenten – eine Übersicht. Kompass Ophthalmol 2020;6:120-126. [DOI: 10.1159/000509813] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345